Artiva Biotherapeutics (ARTV) Equity Ratio (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Equity Ratio data on file, last reported at 0.83 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.83, down 6.05% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.83 (down 6.05% YoY), and the FY2025 annual result was 0.84, down 5.69% from the prior year.
• Equity Ratio slipped to 0.83 in Q1 2026 per ARTV's latest filing, from 0.84 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.89 in Q3 2024 and troughed at 2.52 in Q2 2024.
• A 4-year average of 0.22 and a median of 0.87 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2026: Equity Ratio jumped 157.78% in 2024, then fell 6.05% in 2026.
• A 4-year view of Equity Ratio shows it stood at 1.54 in 2023, then soared by 157.78% to 0.89 in 2024, then declined by 5.69% to 0.84 in 2025, then dropped by 1.28% to 0.83 in 2026.
• Business Quant data shows ARTV's Equity Ratio at 0.83 in Q1 2026, 0.84 in Q4 2025, and 0.87 in Q3 2025.